STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...
Yonhap News Agency on MSN18h
Celltrion launches autoimmune disease treatment in U.S.Celltrion Inc., a major South Korean biopharmaceutical firm, said Thursday it has launched its biosimilar product for Stelara ...
South Korean biopharmaceutical company Celltrion announced Thursday that it has launched Steqeyma (ustekinumab), a biosimilar treatment for autoimmune diseases, in the US market. Steqeyma, a ...
Celltrion's autoimmune disease treatment, SteQeyma, has been launched in five major European nations, the Korean company said Thursday. SteQeyma, an ustekinumab biosimilar treatment for multiple ...
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...
Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.
Celltrion Inc.'s autoimmune disease treatment, SteQeyma, has been launched in five major European nations, the Korean company said Thursday. SteQeyma, an ustekinumab biosimilar treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback